Phaseline

Targets › AADC

AADC (Aromatic-L-amino-acid decarboxylase): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Sep 2030.

Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine and L-5-hydroxytryptophan to serotonin. (UniProt, P20711)

Open in Phaseline: the race on AADC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Vitalgen BioPharmaVGN-R09b
Gene therapy delivering AADC gene to putamen
AADCPhase 2Aromatic L-amino Acid Decarboxylase Deficiency; Parkinson's DiseaseSep 2030

Conditions

Aromatic L-amino Acid Decarboxylase Deficiency (1) Parkinson's Disease (1)

Modalities

other (1)

Companies

Shanghai Vitalgen BioPharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.